Adverse bone effects during pharmacological breast cancer therapy

Acta Oncologica

Volumn 47, Issue 4, 2008, Pages 747-754

  Bjarnason, Nina H ^a   Hitz, Mette ^b   Jorgensen, Niklas R ^b   Vestergaard, Peter ^c  

^a DANISH MEDICINES AGENCY   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETIDRONIC ACID; EXEMESTANE; FLUOROURACIL; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PACLITAXEL; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; TAMOXIFEN CITRATE; TAXANE DERIVATIVE; TRASTUZUMAB; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADVERSE OUTCOME; AMENORRHEA; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE NECROSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRACTURE; GASTROINTESTINAL SYMPTOM; HORMONAL THERAPY; HUMAN; LIFESTYLE; MEDICAL SOCIETY; MONITORING; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SURVIVAL RATE; VERTEBRA FRACTURE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; METABOLISM; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS;

AMENORRHEA; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 45149091588     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802001467     Document Type: Review

References (47)

1. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997-2008.
2. Bruning PF, Pit MJ, Jong-Bakker M, van den EA, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990;61:308-10.
3. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.
4. Fogelman I, Blake GM, Blamey R, Palmer M, Sauerbrei W, Schumacher M, et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003;14:1001-6.
5. Vehmanen L, Saarto T, Elomaa I, Makela P, Valimaki M, Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001;37:2373-8.
6. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15:1341-7.
7. Headley JA, Theriault RL, LeBlanc AD, Vassilopoulou-Sellin R, Hortobagyi GN. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 1998;16:6-11.
8. Shapiro CL, Phillips G, Van Poznak CH, Jackson R, Leboff MS, Woodard S, et al. Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2005;90:41-6.
9. Alexeeva L, Burkhardt P, Christiansen C, Cooper C, Delmas P, Johnell O, et al. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO Study Group. 1st ed. Geneva: WHO Technical Report Series 843. 1994.
10. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-8.
11. ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
12. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
13. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. Randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
14. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007;25:486-92.
15. Mann BS, Johnson JR, Kelly R, Sridhara R, Williams G, Pazdur R. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res 2005;11:5671-7.
16. Theriault RL, Biermann JS, Brown E, Brufsky A, Demers L, Grewal RK, et al. NCCN Task Force Report: Bone Health and Cancer Care. J Natl Compr Cancer Netw 2006;4(Suppl 2):S1-S20.
17. Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, et al. American Society of Clinical Oncology technology assessment working group update: Use of aromatase inhibitors in the adjuvant setting. J Clin Oncol 2003;21:2597-9.
18. National Osteoporosis Foundation. NOF Physician's Guidelines. September 2005. Pharmacologic Options. http://www.nof.org/professionals/clinical.htm. 2005. 20-6-2007.
19. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: Recommendations and rationale. Ann Intern Med 2002; 137:526-8.
20. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57.
21. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: Scientific review. JAMA 2002;288:1889-97.
22. World Health Organization. Prevention and management of osteoporosis: Report of a WHO Scientific Group. WHO Technical Report Series. http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf. 2007. 20-6-2007.
23. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841-50.
24. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-11.
25. NIH State-of-the-Science Conference Statement on Multivitamin/Mineral Supplements and Chronic Disease Prevention. NIH Concens State Sci Statements 2006;23:1-30.
26. Heaney RP. Bone Health. Am J Clin Nutr 2007;85:300S-3S.
27. Ebeling PR, Sandgren ME, DiMagno EP, Lane AW, DeLuca HF, Riggs BL. Evidence of an age-related decrease in intestinal responsiveness to vitamin D: Relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentration in normal women. J Clin Endocrinol Metab 1992;1:176-82.
28. Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. J Lab Clin Med 1978;6:953-63.
29. Van Cromphaut SJ, Rummens K, Stockmans I, Van Herck E, Dijcks FA, Ederveen AG, et al. Intestinal calcium transporter genes are upregulated by estrogens and the reproductive cycle through vitamin D-receptor-independent mechanisms. J Bone Miner Res 2003;10:1725-36.
30. Bronner F. Mechanisms of intestinal calcium absorption. J Cell Biochem 2003;88:387-93.
31. Mosekilde L. Vitamin D and the elderly. Endocrinol (Oxf) 2005;62:265-81.
32. Guéguen L, Pointillart A. The bioavailability of dietary calcium. J Am Coll Nutr 2000;19:119S-36S.
33. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
34. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risendronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52.
35. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.
36. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61.
37. Shiota E, Tsuchiya K, Yamaoka K, Kawano O. Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis. J Orthop Sci 2001;6:133-6.
38. McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis; results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 2007;22:135-41.
39. Vis M, Bultink IE, Dijkmans BA, Lems WF. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis. Osteoporosis Int 2005;16:1432-5.
40. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 1997;15:955-62.
41. Greenspan SL, Bhattacharya RK, Sereika SM, Brufsky A, Vogel VG. Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007;92:131-6.
42. Fuleihan Gel-H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: A randomized controlled trial. J Clin Endocrinol Metab 2005;90:3209-14.
43. Saarto T, Vehmanen L, Elomaa I, Välimäki M, Mäkelä P, Blomqvist C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 2001;84:1047-51.
44. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: The Z-ZO-E-ZO-FAST program. Breast Feb 2006;15(Suppl 1):S30-40.
45. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820-8.
46. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology (Williston Park) 2006;20:1029-39.
47. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: A population-based analysis. J Natl Cancer Inst 2007;99:1016-24.